Search - tctmd.com

Displaying 701 - 720 of 2269

Sort: Relevancy | Date

Drug-Coated Balloons for CAD: Some International Consensus

News

Drug-Coated Balloons for CAD: Some International Consensus

May 27, 2020

COVID-19 in NYC: CV Risk Factors and Bleak Outcomes in the Critically Ill

News Daily News

COVID-19 in NYC: CV Risk Factors and Bleak Outcomes in the Critically Ill

Michael O'Riordan

May 19, 2020

More Evidence of Lower Fracture Risk With DOACs Versus Warfarin

News Daily News

More Evidence of Lower Fracture Risk With DOACs Versus Warfarin

May 19, 2020

PINNACLE FLX: New-Generation Watchman Has High Closure Rates, Good Safety

News Conference News HRS 2020

PINNACLE FLX: New-Generation Watchman Has High Closure Rates, Good Safety

May 15, 2020

P2Y12 Inhibitor Monotherapy Edges Out Aspirin for Secondary Prevention

News Daily News

P2Y12 Inhibitor Monotherapy Edges Out Aspirin for Secondary Prevention

Yael L. Maxwell

May 15, 2020

Subcutaneous ICD Holds Up Well Against Transvenous Devices

News Conference News HRS 2020

Subcutaneous ICD Holds Up Well Against Transvenous Devices

May 13, 2020

New AHA Guidance on Hospital VTE Stresses Risk Assessment, Standardization

News Daily News

New AHA Guidance on Hospital VTE Stresses Risk Assessment, Standardization

Yael L. Maxwell

May 12, 2020

Impella in High-risk Nonemergent PCI: Early Differences Disappear by 1 Year

News Daily News

Impella in High-risk Nonemergent PCI: Early Differences Disappear by 1 Year

May 08, 2020

Anticoagulants May Aid COVID-19 Patients, NYC Data Suggest

News Daily News

Anticoagulants May Aid COVID-19 Patients, NYC Data Suggest

May 06, 2020

Pulmonary Embolism in COVID-19 Patients: New Numbers, Little Consensus

News Daily News

Pulmonary Embolism in COVID-19 Patients: New Numbers, Little Consensus

Michael O'Riordan

April 29, 2020

Clopidogrel Holds Advantage in Older NTSE ACS Patients: POPular AGE Published

News Daily News

Clopidogrel Holds Advantage in Older NTSE ACS Patients: POPular AGE Published

Michael O'Riordan

April 27, 2020

Onyx ONE: Randomized Trial of a Durable-Polymer Drug-Eluting Stent vs a Polymer-Free Drug-Coated Stent in Patients at High Risk of Bleeding Treated With 1-Month DAPT

Podcast TCTMD Talking Points

Onyx ONE: Randomized Trial of a Durable-Polymer Drug-Eluting Stent vs a Polymer-Free Drug-Coated Stent in Patients at High Risk of Bleeding Treated With 1-Month DAPT

April 15, 2020

Cath Lab Dispatch: April 2020

News Opinion CV Team Dispatch

April 2020 News Roundup

April 10, 2020

Edoxaban May Be Alternative to Warfarin After Surgical Valve Implantation or Repair

News Conference News ACC 2020

Edoxaban May Be Alternative to Warfarin After Surgical Valve Implantation or Repair

April 07, 2020

LAAO Registry: Safety of Watchman Looks Good in First Years of Rollout

News Conference News ACC 2020

LAAO Registry: Safety of Watchman Looks Good in First Years of Rollout

April 06, 2020

New Patient-Focused TAVR Quality Score Rolling Out to US Hospitals

News Conference News ACC 2020

New Patient-Focused TAVR Quality Score Rolling Out to US Hospitals

Michael O'Riordan

April 06, 2020

Aspirin Okay for Up to 30 Days

News Conference News ACC 2020

Aspirin Okay for Up to 30 Days in A-fib Patients After ACS or PCI: AUGUSTUS

April 03, 2020

New Questions About Triple Therapy After PAD Revascularization: VOYAGER PAD Substudy

News Conference News ACC 2020

New Questions About Triple Therapy After PAD Revascularization: VOYAGER PAD Substudy

April 02, 2020

Icosapent Ethyl’s CV Benefit Closely Tied to Serum EPA Levels: REDUCE-IT

News Conference News ACC 2020

Icosapent Ethyl’s CV Benefit Closely Tied to Serum EPA Levels: REDUCE-IT

April 02, 2020

Caravaggio Backs Apixaban for Prevention of VTE Recurrence in Cancer Patients

News Conference News ACC 2020

Caravaggio Backs Apixaban for Prevention of VTE Recurrence in Cancer Patients

April 01, 2020

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.